Nautilus Biotechnology Inc Ordinary Shares NAUT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NAUT is a good fit for your portfolio.
News
-
Nautilus Biotechnology to Announce First Quarter 2024 Financial Results on April 30, 2024
-
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2023 Financial Results
-
Nautilus Biotechnology to Participate in the TD Cowen 44ᵗʰ Annual Healthcare Conference
-
Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
Trading Information
- Previous Close Price
- $2.49
- Day Range
- $2.47–2.64
- 52-Week Range
- $2.16–4.65
- Bid/Ask
- $2.49 / $2.65
- Market Cap
- $321.50 Mil
- Volume/Avg
- 53,173 / 78,611
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. It has built a prototype of a single-molecule instrument, Proteomic Analysis System.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 167
- Website
- https://www.nautilus.bio
Comparables
Valuation
|
Metric
|
NAUT
|
SEER
|
VSBC
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 3,629.76 |
Price/Book Value | 1.21 | 0.32 | 1,908.62 |
Price/Sales | — | 8.20 | 664.53 |
Price/Cash Flow | — | — | 2,904.34 |
Price/Earnings
NAUT
SEER
VSBC
Financial Strength
|
Metric
|
NAUT
|
SEER
|
VSBC
|
|---|---|---|---|
Quick Ratio | 19.01 | 24.42 | 4.32 |
Current Ratio | 19.39 | 25.00 | 4.33 |
Interest Coverage | — | — | — |
Quick Ratio
NAUT
SEER
VSBC
Profitability
|
Metric
|
NAUT
|
SEER
|
VSBC
|
|---|---|---|---|
Return on Assets (Normalized) | −15.61% | −11.17% | 42.38% |
Return on Equity (Normalized) | −17.76% | −12.25% | 65.38% |
Return on Invested Capital (Normalized) | −19.72% | −15.40% | 55.23% |
Return on Assets
NAUT
SEER
VSBC
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Mrvgmzgvv | Jnzn | $566.6 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ndttsmsbm | Bdqgjg | $102.4 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Gjvfffg | Gyplxcs | $97.3 Bil | |
MRNA
| Moderna Inc | Ygdlylbjw | Qrhqg | $41.3 Bil | |
ARGX
| argenx SE ADR | Nflsqwwdc | Jshvp | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Bycwthwsj | Ykpg | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Czswfdxpm | Pdbxns | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Lxqqymkxv | Qfhpnd | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Qvxlclsjs | Hmblxd | $12.6 Bil | |
INCY
| Incyte Corp | Vzlbhqqnw | Wyhwrd | $11.6 Bil |